MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing
J15 · Effective Apr 17, 2022
16 active Medicare policies list B02.39, and 1 commercial payer policy lists it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
J15 · Effective Apr 17, 2022
JE · Effective Apr 17, 2022
JF · Effective Apr 17, 2022
JJ · Effective Apr 17, 2022
JM · Effective Apr 17, 2022
J5 · Effective Apr 17, 2022
J8 · Effective Apr 17, 2022
JE · Effective Oct 8, 2018
1 policy from 1 payer
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
| Policy | Effective | Status of B02.39 |
|---|---|---|
| Fluocinolone Acetonide Intra-vitreal Implant (Retisert, Yutiq and Iluvien) | Jan 5, 2024 | Covered |
JF · Effective Oct 8, 2018
J15 · Effective Oct 1, 2015
National · Effective Aug 6, 2026
National · Effective Aug 6, 2026
National · Effective May 14, 2026
J5 · Effective Aug 6, 2026
National · Effective Oct 1, 2026
National · Effective Sep 3, 2026